ArticleCancer2020
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 74 citations in OpenAlex.
- Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.Haematologica · 2022Trial
- D-VRD induction and autologous transplant in patients ≥70 years.Blood cancer journal · 2026Article
- Outcomes of hematopoietic stem cell transplantation in patients aged 70 years and older.Bone marrow transplantation · 2026Article
- The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.Haematologica · 2026Article
- Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia.Internal medicine journal · 2025Article
- Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.Blood advances · 2025Article
- Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m².Annals of transplantation · 2025Article
- Autologous stem cell transplantation in patients older than 65 years with multiple myeloma: a real-world study.Hematology, transfusion and cell therapy · 2024Article
- Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma.British journal of haematology · 2024Article
- Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.Annals of hematology · 2024Article
- Personalized Treatment of Multiple Myeloma in Frail Patients.Current oncology reports · 2024Review
- Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities.Blood cancer journal · 2024Article
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.Cancers · 2024Article
- Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration.Frontiers in immunology · 2024Review
- Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients.Bone marrow transplantation · 2024Article
- Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.Transplantation and cellular therapy · 2023Article
- Do older patients truly benefit from advances in myeloma care?Haematologica · 2023Article
- Partnering With All Patients: Ensuring Shared Decision Making and Evidence-Based Management for Underrepresented Groups With Multiple Myeloma.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2023Article
- Association between low-income subsidies and inequities in orally administered antimyeloma therapy use.The American journal of managed care · 2023Article
- Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
33 authors at 20 institutions in 6 countries.
Pashna N MunshiMedStar Georgetown University Hospital, Washington, DC.
David VesoleJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.
Artur JurczyszynMedicini Department of Hematology, Jagiellonian University Medical College, Krakow, Poland.
Jan Maciej ZauchaDepartment of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland.
Andrew St MartinCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Omar DavilaCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Vaibhav AgrawalDivision of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, Indiana.
Sherif M BadawyDivision of Hematology, Oncology and Stem Cell Transplant, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Minoo BattiwallaSarah Cannon Blood Cancer Network, Nashville, Tennessee.
Saurabh ChhabraCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Edward CopelanDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Mohamed A Kharfan-DabajaDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.
Nosha FarhadfarDivision of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida.ORCID 0000-0002-2752-9604
Siddhartha GangulyDivision of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.
Shahrukh HashmiDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-8914-7927
Maxwell M KremMarkey Cancer Center, University of Kentucky College of Medicine, Lexington, Kentucky.
Hillard M LazarusUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.
Ehsan MalekSeidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.ORCID 0000-0003-4719-4327
Kenneth MeehanNorris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Hemant S MurthyDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.
Taiga NishihoriDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
Rebecca L OlinUniversity of California at San Francisco, San Francisco, California.
Richard F OlssonDepartment of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Jeffrey SchriberCancer Transplant Institute, Virginia G. Piper Cancer Center, Scottsdale, Arizona.
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Gunjan ShahDepartment of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Melhem SolhThe Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, Georgia.
Jason TayTom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.
Shaji KumarDepartment of Hematology, Mayo Clinic Rochester, Rochester, Minnesota.ORCID 0000-0001-5392-9284
Muzaffar H QazilbashThe University of Texas M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2876-2886
Nina ShahUniversity of California at San Francisco, San Francisco, California.ORCID 0000-0002-1971-8173
Parameswaran N HariCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Anita D'SouzaCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.ORCID 0000-0002-1092-5643
Medical College of Wisconsin · USJacksonville College · USMayo Clinic · USUniversity of California, San Francisco · USArizona Oncology · USDartmouth–Hitchcock Medical Center · USDokkyo Medical University · JPGdańsk Medical University · PLGeorgetown University · USHackensack University Medical Center · USIndiana University School of MedicineJagiellonian University · PLLevine Cancer Institute · USMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USNorthside Hospital · USNorthwestern University · USSarah Cannon · USThe University of Texas MD Anderson Cancer Center · USUniversity Hospitals of Cleveland · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MBlood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4MTherapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2MCure Sickle CellOT3HL147741 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI MARY EAPEN, Mary Maresca Horowitz · 2018 to 2026
$37.7MHematopopietic Stem Cell TransplantationU01AI069197 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2005 to 2026
$18.9MRandomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiencyU01AI126612 · NIAID · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S, PULSIPHER, MICHAEL A · 2017 to 2023
$8.5MImmuno and Epigenetics of Hematopoietic Cell TransplantationR01CA218285 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2017 to 2026
$5.6MThe role of TCOF1 in germline predisposition to and in leukemic transformation of chronic myelomonocytic leukemiaR01CA152108 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jing Zhang · 2011 to 2026
$5.4MIntegrated Exchange and Storage of Current- and Future-Generation Immunogenomic DataR01AI128775 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, STEVEN JOHN MACK · 2017 to 2026
$4.5MIdentifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell DonorsR01HL131731 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PULSIPHER, MICHAEL A, SWITZER, GALEN E. · 2018 to 2022
$3.6MIntegrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantationR01CA215134 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S, MAJHAIL, NAVNEET S. · 2017 to 2022
$3.6M'AbbVieActinium Pharmaceuticals IncAdaptive BiotechnologiesAdienne SAAlloVir IncAmgen IncAnthem IncAstellas Pharma USAstraZenecaAtara Biotherapeutics IncBe The Match FoundationBiomedical Advanced Research and Development Authoritybluebird bio IncBoston ChildrenBristol-Myers SquibbCelgene CorporationChimerix IncCSL BehringCytoSen Therapeutics IncDaiichi Sankyo Company LtdDana-Farber Cancer InstituteGamida Cell LtdGenzymeGlaxoSmithKlineHistoGenetics IncHRSA HHS N00014-18-1-2850HRSA HHS N00014-18-1-2888HRSA HHS N00014-20-1-2705Incyte CorporationJanssen Biotech IncJanssen/Johnson & JohnsonJanssen Pharmaceuticals IncJapan Hematopoietic Cell Transplantation Data CenterJazz Pharmaceuticals IncKiadis PharmaKite PharmaKyowa KirinLegend BiotechMagenta TherapeuticsMallinckrodt LLCMedac GmbHMedical College of WisconsinMerck & Company IncMerck Sharp & Dohme CorporationMesoblastMillenniumMiltenyi Biotec IncNational Institute of Allergy and Infectious Diseases U24HL138660National Marrow Donor ProgramNCI NIH HHS OT3HL147741NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA152108NCI NIH HHS R01 CA215134NCI NIH HHS R01 CA218285NCI NIH HHS R01 CA231141NCI NIH HHS R21HL140314NCI NIH HHS U01HL128568NCI NIH HHS U24 CA076518NHLBI NIH HHS HHSH250201700007CNHLBI NIH HHS K23 HL141445NHLBI NIH HHS K23HL141445 HHSH250201700006CNHLBI NIH HHS R01 HL126589NHLBI NIH HHS R01 HL129472NHLBI NIH HHS R01 HL130388NHLBI NIH HHS R01 HL131731NHLBI NIH HHS R21 HL140314NHLBI NIH HHS SC1MC31881-01-00NHLBI NIH HHS U01 HL128568NHLBI NIH HHS U24 HL138660NIAID NIH HHS R01 AI128775NIAID NIH HHS U01 AI069197NIAID NIH HHS U01 AI126612Novartis OncologyNovartis Pharmaceuticals CorporationOmeros CorporationOncoImmune IncOrca Biosystems IncPfizer IncPharmacyclics LLCPublic Health Service U24CA076518Regeneron Pharmaceuticals IncREGiMMUNE CorporationSanofi GenzymeSeattle Geneticss Foundations HospitalSobi IncSt. BaldrickTakeda OncologyTakeda Oncology CorporationTakeda PharmaTerumo BCTViracor EurofinsXenikos BV
Abstract
backgroundUpfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults.
methodsThe authors investigated the outcomes of AHCT in patients with MM who were aged ≥70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged ≥70 years. Nonrecurrence mortality (NRM), disease recurrence and/or progression (relapse; REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models with age at transplantation as the main effect. Because of the large sample size, a P value <.01 was considered to be statistically significant a priori.
resultsAn increase in AHCT was noted in 2017 (28%) compared with 2013 (15%) among patients aged ≥70 years. Although approximately 82% of patients received melphalan (Mel) at a dose of 200 mg/m
conclusionsThe results of the current study demonstrated that AHCT remains an effective consolidation therapy among patients with MM across all age groups.
Indexed as
AgedAged, 80 and overDose-Response Relationship, DrugFemaleHematopoietic Stem Cell TransplantationHumansMaleMelphalanMiddle AgedMultiple MyelomaNeoplasm Recurrence, LocalProgression-Free SurvivalTransplantation, AutologousTreatment OutcomeUnited StatesMelphalanagegeriatric oncologymyelomatransplantation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.